['\xe2\x86\x91 INDICATES INCREASE. \xe2\x86\x93 INDICATES DECREASE. A ONLY IF OTHER DRUGS ARE NOT AVAILABLE AND IF CLEARLY INDICATED. IF TREATMENT WITH LIFE-SUSTAINING DRUGS THAT CAUSE PANCREATIC TOXICITY IS REQUIRED, SUSPENSION OF DIDANOSINE IS RECOMMENDED [SEE WARNINGS AND PRECAUTIONS (5.1) ] . B [SEE WARNINGS AND PRECAUTIONS (5.6) .]', 'DRUGS THAT MAY CAUSE PANCREATIC TOXICITY', '\xe2\x86\x91 RISK OF PANCREATITIS', 'USE ONLY WITH EXTREME CAUTION A', 'NEUROTOXIC DRUGS', '\xe2\x86\x91 RISK OF NEUROPATHY', 'USE WITH CAUTION B', 'ANTACIDS CONTAINING MAGNESIUM OR ALUMINUM', '\xe2\x86\x91 SIDE EFFECTS ASSOCIATED WITH ANTACID COMPONENTS', 'USE CAUTION WITH DIDANOSINE TABLETS FOR ORAL SUSPENSION AND DIDANOSINE PEDIATRIC POWDER FOR ORAL SOLUTION', 'AZOLE ANTIFUNGALS', '\xe2\x86\x93 KETOCONAZOLE OR ITRACONAZOLE CONCENTRATION', 'ADMINISTER DRUGS SUCH AS KETOCONAZOLE OR ITRACONAZOLE AT LEAST 2 HOURS BEFORE DIDANOSINE.', 'QUINOLONE ANTIBIOTICS (SEE ALSO CIPROFLOXACIN IN TABLE 9)', '\xe2\x86\x93 QUINOLONE CONCENTRATION', 'CONSULT PACKAGE INSERT OF THE QUINOLONE.', 'TETRACYCLINE ANTIBIOTICS', '\xe2\x86\x93 ANTIBIOTIC CONCENTRATION', 'CONSULT PACKAGE INSERT OF THE TETRACYCLINE.']